GoodRx, others in talks with White House to join TrumpRx, Reuters reports

Retail pharmacies and prescription drug savings site GoodRx (GDRX) are in discussions with the Trump administration about joining its TrumpRx website, indicating an expansion beyond the early description of it as a link to drugmakers’ direct discounts, Reuters’ Deena Beasley reports. Pharma companies, including Pfizer (PFE) and Amgen (AMGN) are offering to sell some brand-name medicines directly to consumers at the negotiated prices they get from insurers, the author says. Some say they plan tot work with TrumpRx, driven in part by President Trump’s threats of harsh tariffs on drugmakers that don’t lower prices and boost U.S. manufacturing, the author says, noting the site is due to launch in 2026. Other publicly traded companies in the space include AstraZeneca (AZN), Bristol Myers (BMY), Eli Lilly (LLY), GSK (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Roche (RHHBY) and Sanofi (SNY).